Association of gene polymorphisms in RANKL/RANK/OPG system with hypertension and blood pressure in Chinese women

Journal of Human Hypertension

Volumn 29, Issue 12, 2015, Pages 749-753

  Duan, P ^a   Wang, Z M ^a   Liu, J ^a   Wang, L N ^a   Yang, Z ^a   Tu, P ^a  

^a Third Hospital of Nanchang   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; POSTMENOPAUSE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; TNFRSF11A GENE; TNFRSF11B GENE; TNFSF11 GENE; ASIAN CONTINENTAL ANCESTRY GROUP; GENETICS; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CASE-CONTROL STUDIES; FEMALE; HAPLOTYPES; HUMANS; HYPERTENSION; MIDDLE AGED; OSTEOPROTEGERIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 84947028822     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2015.13     Document Type: Article

References (34)

1. Sliwa K, Stewart S, Gersh BJ. Hypertension: a global perspective. Circulation 2011; 123: 2892-2896.
2. Wu Y, Huxley R, Li L, Anna V, Xie G, Yao C, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation 2008; 118: 2679-2686.
3. Wang J, Zhang L, Wang F, Liu L, Wang H China National Survey of Chronic Kidney Disease Working Group. Prevalence, Awareness, Treatment, and Control of Hypertension in China: Results From a National Survey. Am J Hypertens 2014; 27: 1355-1361.
4. Hottenga JJ, Boomsma DI, Kupper N, Posthuma D, Snieder H, Willemsen G, et al. Heritability and stability of resting blood pressure. Twin Res Hum Genet 2005; 8: 499-508.
5. Wu T, Snieder H, Li L, Cao W, Zhan S, Lv J, et al. Genetic and environmental influences on blood pressure and body mass index in Han Chinese: a twin study. Hypertens Res 2011; 34: 173-179.
6. Liu Y, Lou YQ, Liu K, Liu JL, Wang ZG, Wen J, et al. Role of leptin receptor gene polymorphisms in susceptibility to the development of essential hypertension: a case-control association study in a Northern Han Chinese population. J Hum Hypertens 2014; 28: 551-556.
7. Chiang KM, Yang HC, Liang YJ, Chen JW, Hwang SM, Ho HY, et al. A three-stage genome-wide association study combining multilocus test and gene expression analysis for young-onset hypertension in taiwan han chinese. Am J Hypertens 2014; 27: 819-827.
8. Rao AD, Sun B, Saxena A, Hopkins PN, Jeunemaitre X, Brown NJ, et al. Polymorphisms in the serum-And glucocorticoid-inducible kinase 1 gene are associated with blood pressure and renin response to dietary salt intake. J Hum Hypertens 2013; 27: 176-180.
9. Xiong J, O'Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res 2012; 27: 499-505.
10. Papadopouli AE, Klonaris CN, Theocharis SE. Role of OPG/RANKL/RANK axis on the vasculature. Histol Histopathol 2008; 23: 497-506.
11. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490-495.
12. Montagnana M, Lippi G, Danese E, Guidi GC. The role of osteoprotegerin in cardiovascular disease. Ann Med 2013; 45: 254-264.
13. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006; 154: 75-81.
14. Zagura M, Serg M, Kampus P, Zilmer M, Zilmer K, Eha J, et al. Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects. Am J Hypertens 2010; 23: 586-591.
15. Røysland R, Bonaca MP, Omland T, Sabatine M, Murphy SA, Scirica BM, et al. Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart 2012; 98: 786-791.
16. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009; 204: 321-329.
17. Rattazzi M, Bertacco E, Puato M, Faggin E, Pauletto P Hypertension and vascular calcification: a vicious cycle? J Hypertens 2012 30 1885-1893.
18. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
19. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
20. Golledge J, Biros E, Clancy P, Cooper M, Palmer LJ, Norman PE. A single-nucleotide polymorphism in the gene encoding osteoprotegerin is associated with diastolic blood pressure in older men. Am J Hypertens 2009; 22: 1167-1170.
21. Choe WS, Kim HL, Han JK, Choi YE, Seo B, Cho HJ, et al. Association between OPG, RANK and RANKL gene polymorphisms and susceptibility to acute coronary syndrome in Korean population. J Genet 2012; 91: 87-89.
22. Rhee EJ, Yun EJ, Oh KW, Park SE, Park CY, Lee WY, et al. The relationship between Receptor Activator of Nuclear Factor-kappaB Ligand (RANKL) gene polymorphism and aortic calcification in Korean women. Endocr J 2010; 57: 541-549.
23. Brändström H, Stiger F, Lind L, Kahan T, Melhus H, Kindmark A. A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. Biochem Biophys Res Commun 2002; 293: 13-17.
24. Brändström H, Stiger F, Kahan T, Melhus H, Nyström F, öHman KP, et al. A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). Blood Press 2004; 13: 152-157.
25. Kawai T, Ohishi M, Ito N, Onishi M, Takeya Y, Yamamoto K, et al. Alteration of vascular function is an important factor in the correlation between visit-Do-visit blood pressure variability and cardiovascular disease. J Hypertens 2013; 31: 1387-1395.
26. Thanassoulis G, Lyass A, Benjamin EJ, Larson MG, Vita JA, Levy D, et al. Relations of exercise blood pressure response to cardiovascular risk factors and vascular function in the Framingham Heart Study. Circulation 2012; 125: 2836-2843.
27. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95: 1046-1057.
28. Kalra SS, Shanahan CM. Vascular calcification and hypertension: cause and effect. Ann Med 2012; 44: S85-S92.
29. Tousoulis D, Siasos G, Maniatis K, Oikonomou E, Kioufis S, Zaromitidou M, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol 2013; 167: 1924-1928.
30. Huang JW, Lien YC, Yang CY, Liu KL, Wu CF, Yen CJ, et al. Osteoprotegerin, inflammation and dyslipidemia are associated with abdominal aortic calcification in non-diabetic patients on peritoneal dialysis. Nutr Metab Cardiovasc Dis 2014; 24: 236-242.
31. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268.
32. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, López-Ongil S, et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 2009; 104: 1041-1048.
33. Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006; 29: 1664-1666.
34. Zhang W, Wang Q, Wu Y, Moriasi C, Liu Z, Dai X, et al. Endothelial cell-specific liver kinase B1 deletion causes endothelial dysfunction and hypertension in mice in vivo. Circulation 2014; 129: 1428-1439.